Eli Lilly Stock: Setbacks and Alternative Investments in 2026

Eli Lilly's stock experienced a dip following the FDA's decision to extend the review time for orforglipron. This delay allows Novo Nordisk to further establish its presence with oral Wegovy. However, Eli Lilly's Zepbound previously demonstrated its ability to outperform competitors, suggesting that efficacy and application breadth can outweigh initial market entry advantages. Investors are weighing short-term setbacks against long-term potential, considering alternative pharma stocks with more attractive valuations. Merck, with a P/E ratio of just over 14, and Bristol Myers Squibb, with a P/E of 18, offer exposure to cardiometabolic therapies, cancer, and immune disorders, providing diversification beyond the GLP-1 market. While these companies face patent expirations, their history of innovation suggests long-term growth potential.

The FDA extended the review time for Eli Lilly’s oral GLP-1 candidate, orforglipron.

Wegovy gained market advantage due to being an earlier to market oral treatment for weight loss.

Yes, Merck and Bristol Myers Squibb are potential alternatives due to their lower valuations and diverse therapeutic areas.

Do you think Eli Lilly will maintain its leadership in the weight loss market despite recent setbacks? Share this article with others who need to stay ahead of this trend!